ATE301722T1 - Integrin-zielvektoren mit transfektionaktivität - Google Patents

Integrin-zielvektoren mit transfektionaktivität

Info

Publication number
ATE301722T1
ATE301722T1 AT98924478T AT98924478T ATE301722T1 AT E301722 T1 ATE301722 T1 AT E301722T1 AT 98924478 T AT98924478 T AT 98924478T AT 98924478 T AT98924478 T AT 98924478T AT E301722 T1 ATE301722 T1 AT E301722T1
Authority
AT
Austria
Prior art keywords
transfection activity
target vectors
integrin target
integrin
nucleic acid
Prior art date
Application number
AT98924478T
Other languages
German (de)
English (en)
Inventor
Stephen Lewis Hart
Original Assignee
Ich Productions Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ich Productions Ltd filed Critical Ich Productions Ltd
Application granted granted Critical
Publication of ATE301722T1 publication Critical patent/ATE301722T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compression Or Coding Systems Of Tv Signals (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Electrotherapy Devices (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT98924478T 1997-05-29 1998-05-29 Integrin-zielvektoren mit transfektionaktivität ATE301722T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711115.7A GB9711115D0 (en) 1997-05-29 1997-05-29 Integrin-targeting vectors having enhanced transfection activity
PCT/GB1998/001577 WO1998054347A1 (en) 1997-05-29 1998-05-29 Integrin-targeting vectors having transfection activity

Publications (1)

Publication Number Publication Date
ATE301722T1 true ATE301722T1 (de) 2005-08-15

Family

ID=10813246

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98924478T ATE301722T1 (de) 1997-05-29 1998-05-29 Integrin-zielvektoren mit transfektionaktivität

Country Status (9)

Country Link
US (2) US6458026B1 (https=)
EP (1) EP1003898B1 (https=)
JP (1) JP4293292B2 (https=)
AT (1) ATE301722T1 (https=)
AU (1) AU7667398A (https=)
CA (1) CA2288840A1 (https=)
DE (1) DE69831156T2 (https=)
GB (1) GB9711115D0 (https=)
WO (1) WO1998054347A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2405469C (en) 2000-04-12 2012-03-20 Amersham Health As Integrin binding peptide derivatives
AU2001260467A1 (en) * 2000-05-30 2001-12-11 Ich Productions Limited Integrin-targeting vectors having enhanced transfection activity
EP1178117A1 (en) * 2000-08-02 2002-02-06 Erasmus Universiteit Rotterdam Targeting through integrins
NO20004795D0 (no) 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
US8613907B2 (en) * 2000-10-12 2013-12-24 University Of Rochester Compositions that inhibit proliferation of cancer cells
GB0106315D0 (en) 2001-03-14 2001-05-02 Ich Productions Ltd Transfection complexes
RU2294192C2 (ru) * 2001-05-30 2007-02-27 Дзе Скриппс Рисерч Инститьют Система доставки нуклеиновых кислот
BRPI0210886B8 (pt) 2001-07-10 2021-05-25 Amersham Health As composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
US7598421B2 (en) 2002-05-08 2009-10-06 Ucl Biomedica Plc Materials for the delivery of biologically-active material to cells
GB0210538D0 (en) * 2002-05-08 2002-06-19 Univ London Lipids and gene delivery
AU2004233873B2 (en) * 2003-04-25 2010-11-18 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
GB0313132D0 (en) * 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
CA2543257C (en) 2003-10-24 2013-12-31 Gencia Corporation Methods and compositions for delivering polynucleotides
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
WO2007089871A2 (en) * 2006-02-01 2007-08-09 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
US10034674B2 (en) * 2006-02-02 2018-07-31 Steven C Chudik Universal anterior cruciate ligament repair and reconstruction system
GB0610636D0 (en) * 2006-05-30 2006-07-05 Univ London Materials and complexes for the delivery of biologically-active material to cells
RU2010107199A (ru) * 2007-07-31 2011-09-10 Дзе Джонс Хопкинс Юниверсити (Us) Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений
KR101863136B1 (ko) 2008-01-24 2018-05-31 에스퍼란스 파마슈티컬스, 인코포레이티드 용해 도메인 융합 구성물 및 이를 제조하고 사용하는 방법
US20110256055A1 (en) 2008-12-23 2011-10-20 Ge Healthcare Limited Application of 99mtc peptide-based compound as a bone marrow imaging agent
CN118271422A (zh) 2015-08-28 2024-07-02 分子传递有限公司 转染络合物和其使用方法
EP3423438A4 (en) 2016-03-01 2020-05-06 Molecular Transfer, Inc. PLANT VIRUS MOTOR PROTEINS AND METHOD FOR USE THEREOF
GB201604235D0 (en) 2016-03-11 2016-04-27 Ucl Business Plc Lipids and complexes for the delivery of biologically-active material to cells
GB201803419D0 (en) * 2018-03-02 2018-04-18 Ucl Business Plc Complex for the delivery of cas9 proteins guide RNA to cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
AU3876695A (en) 1994-11-17 1996-06-17 Imperial College Of Science, Technology And Medicine Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand
EP0874910A4 (en) 1995-06-07 1999-04-21 Life Technologies Inc ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES
US5908777A (en) 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery

Also Published As

Publication number Publication date
EP1003898A1 (en) 2000-05-31
US20020042384A1 (en) 2002-04-11
US20030013644A1 (en) 2003-01-16
AU7667398A (en) 1998-12-30
DE69831156D1 (de) 2005-09-15
EP1003898B1 (en) 2005-08-10
JP2002502243A (ja) 2002-01-22
DE69831156T2 (de) 2006-06-08
GB9711115D0 (en) 1997-07-23
JP4293292B2 (ja) 2009-07-08
CA2288840A1 (en) 1998-12-03
WO1998054347A1 (en) 1998-12-03
US6458026B1 (en) 2002-10-01

Similar Documents

Publication Publication Date Title
DE69831156D1 (de) Integrin-zielvektoren mit transfektionaktivität
CA2166931A1 (en) Electrostatic bonding type macromolecular micelle drug carrier and drug carried thereon
BR9612677A (pt) Sistemas complementares de vetores adenovírais e linhagens celulares
ZA971159B (en) Target cell-specific vectors for inserting genes into cells, pharmaceuticals comprising such vectors and their use.
EP1019028A4 (en) $ I PROTEIN (CHLAMYDIA), GENE SEQUENCE, AND USES THEREOF
EP0981874A4 (en) OPTIMALLY OPERATIONAL, PROACTIVE CRYPTOSYSTEM WITH PUBLIC KEY AND RELATED METHOD
ZA983930B (en) Excitatory amino acid receptor modulators.
DE69333766D1 (de) Herstellung von phytat-degradierenden enzymen in trichoderma
PT1166775E (pt) Distribuição génica lipossomal direccionada
CA2281206A1 (en) Geranyl diphosphate synthase genes
CA2278808A1 (en) Methods for cultivating cells and propagating viruses
GB9724143D0 (en) Pharmaceutical conjugate
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
CA2014948A1 (en) Genes coding for a protein having human macif activity, expression vectors containing said genes, transformant cells and proteins having human macif activity
WO2001092542A3 (en) Integrin-targeting vectors having enhanced transfection activity
EP1022332A4 (en) BETA FRUCTOFURANOSIDASE AND GENE CODING FOR IT
ATE175866T1 (de) Direktziehendes haarfärbemittel
FI971377L (fi) Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geeniä: itsemurha- ja immuunistimuloiva geeni
NZ334744A (en) Method for determining expression of aberrant forms of APC protein
AU1099697A (en) Novel xylanases, genes encoding them, and uses thereof
WO2001000799A8 (fr) Nouvelle proteine et son adn
WO1998054344A3 (en) Modulators of morphogen expression and methods of identifying the same
EP1041146A4 (en) TUMOR ANTIGEN PROTEIN, ITS GENE AND ITS USE
CA2222594A1 (en) System for distributed task execution
CA2475337A1 (en) Methods for cultivating cells and propagating viruses

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties